Leiden, the Netherlands, Sep 16, 2019 – Today, Batavia Biosciences announces it received a grant of $6.5 million from the Bill & Melinda Gates Foundation to develop a manufacturing process for a novel oral vaccine against polio virus type 2 strain (nOPV2) to help protect children worldwide from future polio outbreaks. In a collaboration with…
Leiden, 3 September 2019 – Today, Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines. Initially, Batavia will deploy the system for production of a potent Zika virus neutralizing antibody, working in…
Leiden, 4 Jul 2019 – Today, Batavia Biosciences announces it received a follow-up grant of $2.2 million from PATH – a global organization dedicated to health equity – to develop and manufacture novel oral poliovirus vaccines (nOPV). The project, which is funded by the Bill & Melinda Gates Foundation, aims to protect children worldwide from…
Grant from the Bill & Melinda Gates Foundation will support Univercells and partner Batavia Biosciences to develop a cost-effective manufacturing process and proceed towards the successful commercialization of measles and rubella vaccines. BRUSSELS, BELGIUM – JUNE, 13 2019 Univercells announced today that it has been awarded a $14.3 million grant by the Bill & Melinda Gates…
Leiden, the Netherlands, May 14, 2019 – Batavia Biosciences announced today that it will work together in a consortium including the European Vaccine Initiative and Stanford University, icddr,b, and headed by the University of Tokyo, to develop an epidemic preparedness vaccine against the Nipah virus. For this purpose, the University of Tokyo received a $31…
The European Union has awarded €15 million to the CardioReGenix consortium, as part of the Horizon2020 program. The research program is initiated to develop new gene therapy approaches for the treatment of heart disease. The program is coordinated by Professor Marinee Chuah from the Free University of Brussels (VUB) and includes thirteen international partners, including…
Leiden, The Netherlands, February 25, 2019 – Batavia Biosciences announced today that it received a $13.2 million grant from the Bill & Melinda Gates Foundation to manufacture clinical-grade inactivated polio vaccine (sIPV), using its newly developed low-cost polio vaccine manufacturing process (marketed as HIP-Vax) based on the NevoLine™ manufacturing technology developed by Univercells. In 2016,…
Univercells, a business-to-business provider focused on increasing the availability of affordable biologics to address global health challenges, announced today the commercial launch of its proprietary NevoLine™ bioproduction system for vaccines. The system was initially developed as part of a $12M Grand Challenges grant awarded by the Bill & Melinda Gates Foundation to deliver affordable inactivated polio vaccine (sIPV). Leading…
Leiden, December 11th, 2018 – Batavia Biosciences announces today that the International AIDS Vaccine Initiative (IAVI) and Batavia Biosciences will work together under a grant to advance the development of a Lassa fever vaccine. With this grant, Batavia Biosciences will leverage its novel, highly intensified manufacturing technology to develop a low-cost, easy-to-implement manufacturing process. This…
We are proud to announce that Batavia Biosciences has again been awarded with an FD Gazelle Award 2018 by the leading Dutch financial newspaper, Financieel Dagblad as one of the fastest growing mid-sized companies of the Netherlands. It is the fourth time we have won an FD Gazelle Award and we hope that many more…